Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online get-togethers and deadlines has returned. And so has volatility in the markets, which reminds us of what happened the last time Chicken Little claimed the sky was falling. The rejoinder, of course, is ‘sell sky.’ Or maybe not. In any event, here are a few tidbits to keep you focused. We hope your day is productive and profitable. Meanwhile, do keep in touch. …
A key U.S. Senate panel is expanding its plans to punish drug makers that hike prices faster than inflation, according to an internal Senate document described to STAT. The policy, which is being considered as part of efforts by Democrats to include drug-pricing reforms in a sweeping government spending package, has the potential to change the way pharmaceutical companies set launch prices for their medicines, and how they choose to adjust prices over time.
The White House has a new headache as it struggles to get its multitrillion-dollar party-line spending bill passed, as Sen. Kyrsten Sinema (D-Ariz.) objects to drug-pricing reforms that are already struggling to make it through the House, Politico reports. Sinema is opposed to the current proposals in both the House and Senate bills and also doesn’t support a pared-back alternative being pitched by House Democratic centrists that would limit the drugs subject to Medicare negotiation.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect